Home / Deep Research / Bipolar Disorder

Bipolar Disorder

Disease Pathophysiology Research Report

2025-12-17
Falcon MONDO:0004985 Model: Edison Scientific Literature 23 citations

Disease Pathophysiology Research Report

Target Disease - Disease Name: Bipolar Disorder - MONDO ID: MONDO_0004985 - Category: Complex

Pathophysiology description (current understanding, 2023–2024 priority) Bipolar disorder (BD) is a polygenic, neurodevelopmentally rooted disorder characterized by recurrent episodes of mania/hypomania and depression with persistent cognitive and functional burden. Convergent molecular evidence implicates dysregulation across: (i) calcium/ion channel signaling and synaptic machinery; (ii) glutamate–GABA and monoaminergic neurotransmission; (iii) immune–inflammatory cascades; (iv) mitochondrial bioenergetics and redox homeostasis; (v) circadian clock mechanisms and neurotrophic/synaptic plasticity pathways; and (vi) oligodendroglial/myelin processes impacting fronto-limbic circuits. Notably, multiple recent syntheses underscore cross-talk between these domains, providing a mechanistic basis for mood state switching, neuroprogression, and cognitive impairment (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

Directly quoted evidence highlights mitochondrial and inflammatory abnormalities and their interplay with synaptic/circadian pathways in BD: “a larger number of smaller-sized mitochondria have been found,” with “downregulation of fusion proteins (Mfn-2, Opa-1) and upregulation of fission (Fis-1), impaired mitophagy, higher cell-free mtDNA,” and a pro-inflammatory milieu (IL-1β, IL-6, TNF-α), alongside “greater activation [of] GSK-3α/β” and “upregulated” PI3K/Akt–mTOR in mania (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). Transcriptomic integration studies emphasize synaptic vesicle release/SNARE complex perturbation, regional specificity (DLPFC, nucleus accumbens, anterior cingulate), and links to insulin/energy pathways (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). iPSC-based reviews report “disturbances in neurodevelopmental processes, imbalance in glutamatergic–GABAergic transmission and neuromorphological alterations” (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2). Clinically, BD associates with increased dementia risk and overlapping risk genes with neurodegeneration, including CACNA1C and SCN2A; meta-analytic estimates show approximately 2–3-fold higher dementia odds in BD (published Aug 20, 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2).

1) Core Pathophysiology - Primary mechanisms - Calcium/ion channel and synaptic signaling: GWAS convergently implicate CACNA1C (L-type Ca2+ channel) and other synaptic/ion channels (e.g., SCN2A) in BD liability; transcriptomics indicate dysregulation of SNARE-mediated synaptic vesicle exocytosis and kinase/phosphoinositide pathways in prefrontal systems (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Sep 2024; https://doi.org/10.3390/biology13100787) (machadovieira2023noncanonicalpathwaysin pages 3-5, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17). - Neurotransmission: Evidence supports altered glutamate–GABA balance and monoaminergic systems; iPSC models show GABA–glutamate imbalance and neuromorphological changes; DRD2- and glutamate-related transcriptomic signals are regionally enriched (Mar 2024; https://doi.org/10.1503/jpn.230112; Sep 2024; https://doi.org/10.3390/biology13100787) (perrottelli2024advancesinthe pages 1-2, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). - Neuroinflammation: Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and inflammasome signaling (e.g., NLRP3) are repeatedly implicated; anti-inflammatory trials yield mixed results, underscoring heterogeneity and the need for biomarker stratification (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Nov 2024; https://doi.org/10.3390/brainsci14121199) (machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Mitochondria, bioenergetics, oxidative stress: Structural/functional mitochondrial abnormalities, impaired mitophagy, and oxidative stress markers are repeatedly observed; PI3K/Akt–mTOR and GSK3 signaling show state-related modulation (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Circadian dysregulation: Clock gene variation and interplay with mitochondrial biogenesis/oxidative stress are noted; circadian mechanisms modulate neuronal survival and treatment response in cellular models (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Oligodendrocyte/myelination: Clinical/imaging syntheses point to white/gray matter injury and myelin-related changes as part of neuroprogression, linked to cognitive deficits (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

2) Key Molecular Players - Genes/Proteins (HGNC) - CACNA1C (L-type CaV1.2 alpha-1 subunit): BD risk and neuropsychiatric pleiotropy; overlaps with dementia risk; calcium signaling–synaptic plasticity (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - SCN2A (Nav1.2): BD–dementia overlap; neuronal excitability (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - ANK3 (ankyrin-G): GWAS-implicated scaffold at AIS/nodes; synaptic/circuit stability (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - GSK3B (GSK3β): Increased activation in mania; ties to Wnt/β-catenin and mood stabilizer targets (Nov 2024; https://doi.org/10.3390/brainsci14121199; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5). - DRD2 (dopamine D2 receptor): Transcriptomic and regional associations (nucleus accumbens); monoaminergic dysregulation (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13). - BDNF (brain-derived neurotrophic factor): Neuroplasticity/synaptic remodeling implicated by systems reviews; interacts with dopaminergic and glutamatergic mechanisms (Sep 2024; https://doi.org/10.3390/biology13100787; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (garcia2024codesbetweenpoles pages 17-19, machadovieira2023noncanonicalpathwaysin pages 3-5). - Mitophagy/mitochondrial dynamics proteins: OPA1, MFN2, FIS1; LC3; apoptosis regulators (BCL2↓, FAS/BAK/APAF1↑) (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10).

3) Biological Processes (GO) disrupted - Synaptic vesicle exocytosis and regulation of neurotransmitter secretion; long-term synaptic plasticity (GO:0016079, GO:0099177, GO:0048167) supported by SNARE-complex and neurotrophin/mTOR signaling changes (Sep 2024; https://doi.org/10.3390/biology13100787; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (garcia2024codesbetweenpoles pages 12-13, machadovieira2023noncanonicalpathwaysin pages 3-5). - Regulation of membrane potential and calcium ion transmembrane transport (GO:0042391, GO:0070588) via CACNA1C/SCN2A dysregulation (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - Inflammatory response and cytokine-mediated signaling (GO:0006954; GO:0019221) including NLRP3–IL-1β/IL-18 axis (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Mitochondrial organization, mitophagy, oxidative phosphorylation, and response to oxidative stress (GO:0007005; GO:0000422; GO:0006119; GO:0006979) (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Circadian rhythm and clock gene transcription feedback loops (GO:0007623; GO:0006342 related to chromatin/cycle regulation) linking to survival pathways (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Myelination and axon ensheathment (GO:0042552; GO:0008366) with white matter connectivity consequences (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

4) Cellular Components (GO) - Synapse, presynaptic active zone, postsynaptic density (GO:0045202; GO:0048786; GO:0014069) (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13). - Mitochondrion, mitochondrial inner membrane, mitophagosome (GO:0005739; GO:0005743; GO:0000422) (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Node of Ranvier/axon initial segment (ANK3 scaffolding), myelin sheath (GO:0030674; GO:0043209) (Nov 2024; https://doi.org/10.3390/brainsci14121199; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5).

5) Disease Progression - Sequence of events (hypothesis-driven): 1) Genetic predisposition (polygenic risk in calcium/ion channels and synaptic genes) and developmental perturbations alter early neural circuit maturation (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776; Mar 2024; https://doi.org/10.1503/jpn.230112) (hirakawa2024thegeneticassociation pages 1-2, perrottelli2024advancesinthe pages 1-2). 2) Vulnerable circuits (fronto-limbic–striatal and cerebellar contributions) exhibit E/I imbalance and synaptic plasticity deficits under stressors (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Sep 2024; https://doi.org/10.3390/biology13100787) (machadovieira2023noncanonicalpathwaysin pages 3-5, garcia2024codesbetweenpoles pages 16-17). 3) Bioenergetic strain and oxidative stress with impaired mitophagy lead to “smaller-sized mitochondria,” apoptotic signaling, and inflammatory amplification (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). 4) Myelin/white-matter injury and synaptic dysfunction contribute to neuroprogression and cognitive decline, with epidemiologic links to later-life dementia risk (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (machadovieira2023noncanonicalpathwaysin pages 3-5, hirakawa2024thegeneticassociation pages 1-2).

6) Phenotypic manifestations and mechanistic links - Core clinical phenotypes (HP terms): mania (HP:0000718), depression (HP:0000716), sleep/circadian disturbance (HP:0002360), cognitive impairment (HP:0100543). Mechanistically, E/I imbalance and synaptic plasticity failure in DLPFC–ACC–limbic networks relate to affective lability and executive/memory deficits. The increased dementia risk in BD (OR ~2.36–2.96) supports neuroprogressive processes bridging mitochondrial, inflammatory, and synaptic/myelin pathology (published Aug 20, 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2), consistent with white/gray matter involvement and inflammatory–kynurenine axes (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

Recent developments and latest research (2023–2024 priority) - Non-canonical pathways integrating immune–mitochondrial–synaptic axes, with mixed but instructive anti-inflammatory RCT signals; emphasis on NLRP3, lipid–eicosanoid signaling, and microbiome–immune interventions (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Mitochondrial dynamics/mitophagy and mood-state signaling (GSK3, PI3K/Akt–mTOR) refined as episode-linked biomarkers; circadian–mitochondrial cross-talk proposed (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Transcriptomic regionalization: DLPFC (synaptic/insulin pathways), ACC and nAcc (glutamate/dopamine genes) with SNARE complex involvement; lithium-related hippocampal plasticity (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). - iPSC models extend causal inference on neurodevelopmental deficits and E/I imbalance in BD and schizophrenia spectra (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2). - Genetic cross-disorder overlap with dementia, highlighting CACNA1C and SCN2A in BD neuroprogression and cognitive risk trajectories (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2).

Current applications and real-world implementations - Mood stabilizers (e.g., lithium) and atypical antipsychotics act partly via neuroplasticity/PKC–GSK3 and synaptic signaling; lithium-associated hippocampal volume maintenance aligns with neurotrophic hypotheses (Sep 2024; https://doi.org/10.3390/biology13100787; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (garcia2024codesbetweenpoles pages 17-19, machadovieira2023noncanonicalpathwaysin pages 3-5). - Anti-inflammatory strategies (minocycline, infliximab) show mixed efficacy overall but signal in biomarker-defined subgroups (e.g., childhood maltreatment), motivating stratified trials (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Translational disease modeling with iPSCs/organoids enables patient-specific interrogation of synaptic, mitochondrial, and developmental phenotypes for target discovery (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2).

Expert opinions and analysis from authoritative sources - Frontiers in Neuroscience (Aug 2023) authors argue BD is best conceptualized as a systems disorder with “immune-inflammatory mechanisms,” mitochondrial threshold effects (bioenergetics/ROS/Ca2+), and synaptic/myelin consequences, requiring multimodal treatment development (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Brain Sciences (Nov 2024) review synthesizes a mechanistic cascade from mitochondrial dynamics and impaired mitophagy to apoptosis and inflammatory amplification, linking to episode-specific kinase signaling (GSK3, mTOR) and circadian–mitochondrial coupling (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - J Psychiatry & Neuroscience (Mar 2024) highlights iPSC evidence for glutamate–GABA imbalance and neurodevelopmental disruptions as convergent features across BD and schizophrenia spectrum (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2).

Relevant statistics and data from recent studies - Dementia risk: Two meta-analytic estimates cited in an Aug 2024 review reported increased dementia odds in BD of OR 2.36 (95% CI 1.36–4.09) and OR 2.96 (95% CI 2.09–4.18) (Aug 20, 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - Mitochondrial morphology/dynamics: “larger number of smaller-sized mitochondria” with fusion (Mfn-2/Opa-1) down and fission (Fis-1) up; increased cell-free mtDNA; mitophagy/apoptosis markers altered (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Anti-inflammatory RCTs: minocycline positive in some, null in factorial designs; infliximab ineffective overall but signals in maltreatment subgroup; meta-analyses suggest insufficient evidence for routine NSAIDs/omega-3/pioglitazone, limited single-study support for NAC (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

Ontology-anchored annotations (selected examples) - Genes/Proteins (HGNC): CACNA1C; SCN2A; ANK3; GSK3B; DRD2; BDNF (hirakawa2024thegeneticassociation pages 1-2, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 17-19). - Biological Processes (GO): synaptic vesicle exocytosis; regulation of calcium transport; cytokine-mediated signaling; mitophagy; oxidative phosphorylation; circadian rhythm; myelination (garcia2024codesbetweenpoles pages 12-13, machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Cellular Components (GO): synapse/PSD; mitochondrion/inner membrane; mitophagosome; myelin sheath; node of Ranvier/AIS (garcia2024codesbetweenpoles pages 12-13, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5). - Cell types (CL): neuron; microglia; astrocyte; oligodendrocyte (perrottelli2024advancesinthe pages 1-2, machadovieira2023noncanonicalpathwaysin pages 3-5). - Anatomical Locations (UBERON): DLPFC; ACC; nucleus accumbens; hippocampus (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). - Chemical entities (CHEBI): glutamate; GABA; dopamine; serotonin (perrottelli2024advancesinthe pages 1-2, garcia2024codesbetweenpoles pages 12-13). - Phenotypes (HP): mania; depressive episode; cognitive impairment; sleep disturbance (hirakawa2024thegeneticassociation pages 1-2, machadovieira2023noncanonicalpathwaysin pages 3-5).

Evidence Items (selected, with URLs and dates) - Machado-Vieira et al. “Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.” Frontiers in Neuroscience. Published Aug 2023. URL: https://doi.org/10.3389/fnins.2023.1228455 (machadovieira2023noncanonicalpathwaysin pages 3-5). - Giménez-Palomo et al. “Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review.” Brain Sciences. Nov 2024. URL: https://doi.org/10.3390/brainsci14121199 (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Perrottelli et al. “Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through iPSC models.” J Psychiatry & Neuroscience. Mar 2024. URL: https://doi.org/10.1503/jpn.230112 (perrottelli2024advancesinthe pages 1-2). - Garcia & Tayo. “Codes between Poles: Transcriptomic Insights…” Biology. Sep 2024. URL: https://doi.org/10.3390/biology13100787 (garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 17-19). - Hirakawa & Terao. “The genetic association between bipolar disorder and dementia.” Frontiers in Psychiatry. Aug 20, 2024. URL: https://doi.org/10.3389/fpsyt.2024.1414776 (hirakawa2024thegeneticassociation pages 1-2).

Notes and limitations - Many mechanistic domains show heterogeneity across studies. Anti-inflammatory interventions require biomarker-guided stratification; mitochondrial/synaptic markers vary by episode/state. iPSC studies, while highly informative, require standardization and deeper phenotypic anchoring (Mar 2024; https://doi.org/10.1503/jpn.230112; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (perrottelli2024advancesinthe pages 1-2, machadovieira2023noncanonicalpathwaysin pages 3-5).

Summary BD pathophysiology reflects convergent dysregulation of calcium/ion channel–synaptic systems, glutamate–GABA and monoamines, immune–inflammatory cascades, mitochondrial/oxidative pathways, and circadian and neurotrophic plasticity, with oligodendroglial/myelin changes impairing fronto-limbic networks. State-associated kinase signaling (GSK3, PI3K/Akt–mTOR), impaired mitophagy/oxidative stress, and cytokine activation provide plausible mechanisms for mood switches and neuroprogression with measurable cognitive risk. This multi-axis model is supported by 2023–2024 evidence from genetics, transcriptomics, mitochondria-focused reviews, and iPSC studies and motivates biomarker-stratified, circuit- and pathway-targeted therapeutics (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Nov 2024; https://doi.org/10.3390/brainsci14121199; Mar 2024; https://doi.org/10.1503/jpn.230112; Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, perrottelli2024advancesinthe pages 1-2, hirakawa2024thegeneticassociation pages 1-2).

References

  1. (machadovieira2023noncanonicalpathwaysin pages 3-5): Rodrigo Machado-Vieira, Alan C. Courtes, Carlos A. Zarate, Ioline D. Henter, and Husseini K. Manji. Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder. Frontiers in Neuroscience, Aug 2023. URL: https://doi.org/10.3389/fnins.2023.1228455, doi:10.3389/fnins.2023.1228455. This article has 14 citations and is from a peer-reviewed journal.

  2. (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10): Anna Giménez-Palomo, Helena Andreu, Oscar de Juan, Luis Olivier, Iñaki Ochandiano, Lidia Ilzarbe, Marc Valentí, Aldo Stoppa, Cristian-Daniel Llach, Giulio Pacenza, Ana Cristina Andreazza, Michael Berk, Eduard Vieta, and Isabella Pacchiarotti. Mitochondrial dysfunction as a biomarker of illness state in bipolar disorder: a critical review. Brain Sciences, 14:1199, Nov 2024. URL: https://doi.org/10.3390/brainsci14121199, doi:10.3390/brainsci14121199. This article has 13 citations and is from a poor quality or predatory journal.

  3. (garcia2024codesbetweenpoles pages 12-13): Jon Patrick T. Garcia and Lemmuel L. Tayo. Codes between poles: linking transcriptomic insights into the neurobiology of bipolar disorder. Biology, 13:787, Sep 2024. URL: https://doi.org/10.3390/biology13100787, doi:10.3390/biology13100787. This article has 4 citations and is from a poor quality or predatory journal.

  4. (garcia2024codesbetweenpoles pages 16-17): Jon Patrick T. Garcia and Lemmuel L. Tayo. Codes between poles: linking transcriptomic insights into the neurobiology of bipolar disorder. Biology, 13:787, Sep 2024. URL: https://doi.org/10.3390/biology13100787, doi:10.3390/biology13100787. This article has 4 citations and is from a poor quality or predatory journal.

  5. (garcia2024codesbetweenpoles pages 17-19): Jon Patrick T. Garcia and Lemmuel L. Tayo. Codes between poles: linking transcriptomic insights into the neurobiology of bipolar disorder. Biology, 13:787, Sep 2024. URL: https://doi.org/10.3390/biology13100787, doi:10.3390/biology13100787. This article has 4 citations and is from a poor quality or predatory journal.

  6. (perrottelli2024advancesinthe pages 1-2): Andrea Perrottelli, Francesco Flavio Marzocchi, Edoardo Caporusso, Giulia Maria Giordano, Luigi Giuliani, Antonio Melillo, Pasquale Pezzella, Paola Bucci, Armida Mucci, and Silvana Galderisi. Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models. Journal of Psychiatry & Neuroscience : JPN, 49:E109-E125, Mar 2024. URL: https://doi.org/10.1503/jpn.230112, doi:10.1503/jpn.230112. This article has 14 citations.

  7. (hirakawa2024thegeneticassociation pages 1-2): Hirofumi Hirakawa and Takeshi Terao. The genetic association between bipolar disorder and dementia: a qualitative review. Frontiers in Psychiatry, Aug 2024. URL: https://doi.org/10.3389/fpsyt.2024.1414776, doi:10.3389/fpsyt.2024.1414776. This article has 1 citations and is from a poor quality or predatory journal.